NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Indivior Pharmaceuticals, Inc. INDV
4 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 1.2B
Revenue, FY2025 · full 4-year series below
Revenue $B
Net income $B
FY2025 · Revenue 1.2 · Net income 0.2
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
17 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 21.1% · Net 16.9%
ROE
Not applicable: equity was negative in this period, so return on equity has no meaning.
The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 1.2 | 1.2 | 1.1 | 0.9 |
| Operating income $B | 0.3 | 0.0 | −0.2 | −0.1 |
| EBITDA $B | 0.3 | 0.1 | −0.1 | −0.1 |
| Income tax $B | 0.0 | 0.0 | −0.0 | −0.0 |
| Net income $B | 0.2 | 0.0 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | 0.0 | −0.3 | −0.0 |
| EPS, diluted $ | 1.64 | 0.05 | −0.92 | −0.32 |
| Dividend / sh $ | · | · | · | · |
| Payout % | · | · | · | · |
| ROE % | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 18 reconciliationsAUDITED
Reconciled in 4 of 19 fiscal years. 77 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2022